Answers are grounded in this paper and cite their sources.
Retrospective analysis shows lower mortality in overweight and obese B-cell lymphoma patients treated with rituximab, suggesting an unexpected survival advantage.
The association between obesity and survival in non-Hodgkin lymphoma is unclear. Using the Ontario Cancer Registry we conducted a retrospective analysis of incident cases of aggressive-histology B-cell lymphoma treated with a rituximab-containing regimen with curative intent between 2008–2016. 6246 patients were included. On multivariable analysis the rate of all-cause mortality was lower for the overweight body mass index (BMI 25–29.9 kg/m2) (HR 0.85; 95%CI 0.77–0.95) and obese BMI (≥30 kg/m2) (HR 0.75; 95%CI 0.67–0.85) groups compared to the normal weight group (18.5–24.9 kg/m2). Binomial logistic regression analysis revealed a lower odds ratio (OR) of admission to hospital during treatment in the overweight (OR 0.84; 95%CI 0.75–0.95) compared to normal weight BMI group. In the largest cohort to date of aggressive-histology B-cell lymphoma patients treated with rituximab, increased BMI is associated with a survival advantage, and the magnitude of this effect increases from overweight to obese BMI.
No takes yet. Share an insight, caveat, or question.
Stevenson et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: